Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

RISE: Rapid Recovery Through Integrated Substance Use Treatment and Written Exposure for PTSD

NCT07903753 is registered in ClinicalTrials.gov with VA Office of Research and Development as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07903753 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
RISE: Rapid Recovery Through Integrated Substance Use Treatment and Written Exposure for PTSD
Lead sponsor
VA Office of Research and Development
Phase
Not applicable
Overall status
Not yet recruiting
Start date
August 1, 2028
Completion date
July 31, 2030
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

Arms

As registered; 2 arms.

  • RISE ExperimentalCognitive Behavioral Therapy for Substance Use Disorders (skill components), Written Exposure Therapy

    An intervention that integrates Written Exposure Therapy (WET) for PTSD with core components of Cognitive Behavioral Therapy for Substance Use Disorder (CBT-SUD), delivered over six weekly, 90-minute individual sessions.

  • CBT-SUD Active comparatorCognitive Behavioral Therapy for Substance Use Disorders

    An evidence-based, individually delivered Cognitive Behavioral Therapy for Substance Use Disorder, delivered over six weekly, 90-minute sessions matched to RISE for total clinical contact time.

Primary endpoints

Registered primary outcome measures; 6 primary.

  • Feasibility: Participant Recruitment Baseline

    Rate of eligible screened Veterans and enrollment rate, used as an indicator of the reach and accessibility of RISE.

  • Feasibility: Study Retention post-treatment (6 weeks), 3-month follow-up

    Proportion of enrolled participants retained through study completion.

  • Feasibility: Number of Sessions Attended 6 weeks

    Average number of treatment sessions attended by participants in each arm, used as a behavioral indicator of treatment engagement.

  • Feasibility: Treatment Completion 6 weeks

    Proportion of participants who complete all six treatment sessions, used as a behavioral indicator of feasibility.

  • Feasibility: Study Withdrawals post-treatment (6 weeks), 3-month follow-up

    Number and proportion of participants who withdraw from the study prior to treatment completion.

+1 more primary endpoint

Lead sponsor's other trials

VA Office of Research and Development, most recent start first.

Similar trials

Same condition (Stress Disorders, Post-Traumatic) and phase, most recent start first.